STAT3 Signaling in Glioblastoma Pathogenesis

Signal transducer and activator of transcription 3 (STAT3) plays a central role in the initiation and progression of glioblastoma, the most aggressive primary brain tumour in adults. Persistent activation of STAT3 in malignant glioma cells drives proliferation, migration and invasion through upregulation of genes involved in cell cycle progression, anti-apoptotic pathways and angiogenesis. Within the tumour microenvironment, STAT3 signalling fosters immunosuppression by promoting the secretion of tolerogenic cytokines and reducing the activity of cytotoxic lymphocytes. In glioma stem cells, STAT3 supports stemness and therapy resistance, in part by interacting with other pathways such as EGFR, NF-κB and Notch. Therapeutic approaches aimed at inhibiting STAT3 signalling have demonstrated efficacy in preclinical models, restoring chemosensitivity to temozolomide, impairing stem-cell-like properties and reshaping the immune milieu. These findings underscore STAT3 as a multifaceted driver of glioblastoma pathogenesis and a promising target for novel interventions.

Research from Nature Portfolio

Recent work has established a STAT3-based gene signature capable of stratifying glioblastoma patients according to STAT3 activation status. High-STAT3 tumours exhibit a mesenchymal transcriptional profile and are selectively sensitive to STAT3 inhibition in preclinical xenograft models. Furthermore, combining STAT3 inhibitors with blockade of compensatory kinases, such as IGF-1R, overcomes resistance in STAT3-low tumours and improves survival. This study illustrates the importance of serial molecular profiling to guide precision targeting of STAT3 and allied pathways to counter intratumour heterogeneity and adaptive signalling in glioblastoma.

STAT3 Signaling in Glioblastoma Pathogenesis publication trend

The graph below shows the total number of articles in stat3 signaling in glioblastoma pathogenesis across all publications each year (not limited to Nature Index journals).

Technical terms

STAT3: Signal transducer and activator of transcription 3, a transcription factor activated by phosphorylation that regulates genes controlling proliferation, survival and immunomodulation.

Glioblastoma: The most aggressive primary brain tumour in adults, marked by rapid proliferation, invasive growth and resistance to therapy.

Temozolomide (TMZ): An oral alkylating agent standardly used to treat glioblastoma, acting by methylating DNA and inducing tumour cell death.

JAK3: Janus kinase 3, a cytoplasmic tyrosine kinase that phosphorylates STAT3 in response to cytokine signalling.

Long non-coding RNA (lncRNA): Non-protein-coding transcripts over 200 nucleotides in length that regulate gene expression through diverse mechanisms.

References

1. RPL22L1, a novel candidate oncogene promotes temozolomide resistance by activating STAT3 in glioblastoma. Cell Death & Disease (2023).
2. Pyrimidine compounds BY4003 and BY4008 inhibit glioblastoma cells growth via modulating JAK3/STAT3 signaling pathway. Neurotherapeutics (2024).
3. HOXD‐AS2‐STAT3 feedback loop attenuates sensitivity to temozolomide in glioblastoma. CNS Neuroscience & Therapeutics (2023).
4. A STAT3-based gene signature stratifies glioma patients for targeted therapy. Nature Communications (2019).